The study looks at a lot of things but to me the most surprising was that MSD has only 1,842 pwME receiving benefits on their record
If this number was representative - unlikely - it would suggest a prevalence of 0.06%
Agree. Huge data gap. To be clear, Nick stresses that they're far from capturing everyone and he doesn't believe the 0.06% is anywhere near reflecting reality. The problem is - once again - that we don't have any better dataIt wouldn't show up people supported financially by their families, then, or who are too young to work or have reached pension age.
Given the peak ages of onset—teenage years, when affected people are likely to remain with their parents, and middle age, when the loss of one income might not leave a family hard up enough to qualify for social security—that's a big gap in the data.
Nick has received a grant to look into the prevalence of autism in NZ. Interesting because autism very likely also has significant diagnostic inconsistency issues that make the usual public and medical records unreliable. Unfortunately the newspaper doesn't say how Nick is planning on dealing with this problem but he has a little more money to do so (NZ$124,442) than he had for doing the same for ME (assuming he only had the ANZMES grant of $25,000, I don't actually know)Nick Bowden's presentation (see post #20)
Interesting talk. Lots of (preliminary) data to mull over
However, this study demonstrates yet again how difficult it is to get any representative population level data for ME
2023 application round is open 31 May - 31 July
press release: https://anzmes.org.nz/grant-and-scholarship-programme/
programme description: https://anzmes.org.nz/research-funding-programme/
It's interesting to note the wording used: the grants haven't gone to laboratory research studies.There will be six funding opportunities awarded each year to Postgraduates who undertake research that furthers understanding, treatment, or prevention of ME/CFS and long COVID, including two $25,000 grants to support laboratory research studies and four $5,000 scholarships to support students undertaking research projects. Academic researchers can also apply for the grants.
”press release” said:ANZMES is delighted to confirm that Dr. Natalia Boven of the COMPASS Research Centre at the University of Auckland has been awarded a $25,000 Grant as part of the 2025 funding round. This Grant will contribute towards the costs of her project, titled “Identifying child and adolescent predictors of adult ME/CFS and Long COVID,” which will use linked administrative data to explore the association between childhood health conditions – particularly those linked to dysfunctional mast cell activation (MCAS) – and the risk of developing ME/CFS and Long COVID in early adulthood. The research team at the University of Auckland includes Dr. Anna Brooks, Keith McLeod, Dr. Nick Bowden (a 2023 ANZMES grant recipient), Dr. Lisa Underwood, Dr. Nicola Gillies, and Dr. David Musson. This crucial study is intended to help reduce diagnostic delays, inform risk mitigation strategies, and contribute to understanding underlying pathophysiology.
More at link”press release” said:ANZMES is also pleased to announce Galina Mandich of the University of Otago as the recipient of a $10,000 research scholarship. The funding will support a 10-week summer research project, providing a $7,000 internship stipend and $3,000 for research materials and expenses. The study is titled: “Development of a genetic susceptibility test for developing Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID: Has the large 2025 Decode ME GWAS study provided a key advance?”. The study, conducted alongside Emeritus Professor Warren Tate and Katie Peppercorn, will analyse blood samples in families where multiple members are impacted by ME/CFS and Long COVID. The aim is to identify common genetic markers or a ‘signature’ shared between them. This signature could be a significant step towards earlier diagnosis, treatment, and improved outcomes for those impacted by these debilitating conditions.
Congrats to the recipients!2025 grant & scholarship winners announced, 1 each
”Tate’s donation page” said:(B) A genetic test for susceptibility to developing ME/CFS and Long COVID
A recent technical breakthrough has revealed certain combinations of naturally occurring genetic variations in the DNA genome can account for most of the samples from ME/CFS patients in the UK biobank. These variations can account for why 5-10% of the population are susceptible to developing the post-viral sydromes, ME/CFS and Long COVID, when exposed to a triggering stress event. In preliminary studies we have shown our NZ patients also have some of these combinations of the single base variations. In 2025 we are investigating whether it is possible to develop a test for susceptibility within affected families by establishing a family molecular signature that would indicate high risk or not. We now are recruiting families to test whether such an individual family risk signature can be identified and then used to detect susceptibility among those unaffected family members. It would then be possible for those individuals at risk to take prophylactic protective measures if they were exposed to a typical triggering event like a viral infection or a major stress event, and prevent them succumbing to the long term syndromes.